A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Former exenatide brand Byetta has, according to Diabetes UK, been discontinued. Much like other GLP-1 receptor agonists, lixisenatide binds to and activates the GLP-1 receptor, increasing insulin ...